CMML
MCID: CHR285
MIFTS: 59

Chronic Myelomonocytic Leukemia (CMML)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Chronic Myelomonocytic Leukemia

MalaCards integrated aliases for Chronic Myelomonocytic Leukemia:

Name: Chronic Myelomonocytic Leukemia 11 19 58 75 28 5 14 36 16
Leukemia, Myelomonocytic, Chronic 19 71
Chronic Myelomonocytic Leukaemia Without Mention of Remission 33
Cmml - [chronic Myelomonocytic Leukaemia] 33
Leukemia Myelomonocytic Chronic 53
Chronic Monocytoid Leukaemia 33
Chronic Monocytic Leukaemia 33
Cmml 58

Characteristics:


Prevelance:

1-9/1000000 (Europe) 58

Age Of Onset:

Adult 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:0080188
NCIt 49 C3178
ICD10 31 C93.1
MESH via Orphanet 44 D015477
ICD10 via Orphanet 32 C93.1
UMLS via Orphanet 72 C0023480
Orphanet 58 ORPHA98823
ICD11 33 2073226578
UMLS 71 C0023480

Summaries for Chronic Myelomonocytic Leukemia

GARD: 19 A rare myelodysplastic/myeloproliferative neoplasm characterized by a spectrum of clinical, hematological, and morphological features, ranging from predominantly myelodysplastic to mainly myeloproliferative in nature. Infiltration of the liver, spleen, lymph nodes, and other organs is common. Persistent peripheral blood monocytosis with monocytes accounting for more than 10% of leukocytes is the hallmark of the condition. Blasts constitute less than 20% of the cells in the peripheral blood and bone marrow. Other abnormalities are variable. Patients may present with constitutional symptoms, signs and symptoms of hematopoietic insufficiency, and hepatosplenomegaly. The disease is associated with a risk of transformation to acute myeloid leukemia.

MalaCards based summary: Chronic Myelomonocytic Leukemia, also known as leukemia, myelomonocytic, chronic, is related to juvenile myelomonocytic leukemia and myelodysplastic syndrome, and has symptoms including fatigue, fever and night sweats. An important gene associated with Chronic Myelomonocytic Leukemia is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are Disease and Akt Signaling. The drugs homoharringtonine and Daunorubicin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and monocytes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

Orphanet: 58 A rare myelodysplastic/myeloproliferative neoplasm characterized by a spectrum of clinical, hematological, and morphological features, ranging from predominantly myelodysplastic to mainly myeloproliferative in nature. Infiltration of the liver, spleen, lymph nodes, and other organs is common. Persistent peripheral blood monocytosis with monocytes accounting for more than 10% of leukocytes is the hallmark of the condition. Blasts constitute less than 20% of the cells in the peripheral blood and bone marrow. Other abnormalities are variable. Patients may present with constitutional symptoms, signs and symptoms of hematopoietic insufficiency, and hepatosplenomegaly. The disease is associated with a risk of transformation to acute myeloid leukemia.

Disease Ontology: 11 A chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.

Wikipedia: 75 Chronic myelomonocytic leukemia (CMML) is a type of leukemia, which are cancers of the blood-forming... more...

Related Diseases for Chronic Myelomonocytic Leukemia

Diseases in the Acute Myelomonocytic Leukemia family:

Juvenile Myelomonocytic Leukemia Chronic Myelomonocytic Leukemia

Diseases related to Chronic Myelomonocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 456)
# Related Disease Score Top Affiliating Genes
1 juvenile myelomonocytic leukemia 32.7 U2AF1 TET2 SRSF2 SETBP1 RUNX1 PTPN11
2 myelodysplastic syndrome 32.3 U2AF1 TOP1 TET2 SRSF2 SETBP1 RUNX1
3 myelodysplastic/myeloproliferative neoplasm 32.2 U2AF1 TET2 SRSF2 SETBP1 PTPN11 PDGFRB
4 leukemia 32.2 U2AF1 RUNX1 PTPN11 PDGFRB NF1 KIT
5 refractory anemia 31.8 TET2 ASXL1
6 myeloproliferative neoplasm 31.8 U2AF1 TET2 SRSF2 RUNX1 PTPN11 PDGFRB
7 leukemia, acute myeloid 31.7 U2AF1 TOP1 TET2 SRSF2 SETBP1 RUNX1
8 acute leukemia 31.6 TOP1 SETBP1 RUNX1 KIT JAK2 GATA2
9 myeloid leukemia 31.5 U2AF1 TET2 SETBP1 RUNX1 PTPN11 PDGFRB
10 refractory anemia with excess blasts 31.5 U2AF1 TET2 SETBP1 GATA2 ASXL1
11 thrombocytopenia 31.5 U2AF1 TOP1 RUNX1 PTPN11 KIT JAK2
12 acute myelomonocytic leukemia 31.4 RUNX1 KIT FLT3 ETV6 CSF1
13 hypereosinophilic syndrome 31.4 PDGFRB KIT JAK2 CSF2
14 hematologic cancer 31.4 U2AF1 TOP1 RUNX1 PTPN11 PDGFRB KIT
15 leukemia, chronic myeloid 31.4 U2AF1 TET2 SETBP1 RUNX1 PTPN11 PDGFRB
16 mastocytosis 31.4 TET2 SRSF2 PDGFRB KIT JAK2 FLT3
17 myelofibrosis 31.4 U2AF1 TET2 SRSF2 SETBP1 RUNX1 PDGFRB
18 systemic mastocytosis 31.3 U2AF1 TET2 SRSF2 PTPN11 PDGFRB KIT
19 pancytopenia 31.3 U2AF1 RUNX1 KIT FLT3 CSF2 CSF1
20 aplastic anemia 31.3 U2AF1 GATA2 FLT3 CSF3R CSF2 CSF1
21 atypical chronic myeloid leukemia, bcr-abl1 negative 31.3 U2AF1 TET2 SRSF2 SETBP1 PDGFRB JAK2
22 neutropenia 31.2 TOP1 PTPN11 JAK2 FLT3 CSF3R CSF2
23 thrombocytosis 31.2 U2AF1 TET2 JAK2 CSF2 ASXL1
24 deficiency anemia 31.2 U2AF1 KIT JAK2 FLT3 CSF3R CSF2
25 polycythemia vera 31.2 U2AF1 TET2 PTPN11 PDGFRB KIT JAK2
26 chronic neutrophilic leukemia 31.1 U2AF1 TET2 SRSF2 SETBP1 JAK2 CSF3R
27 neutrophilia, hereditary 31.1 U2AF1 JAK2 FLT3 CSF3R CSF2
28 leukemia, chronic lymphocytic 31.1 U2AF1 TET2 SRSF2 PTPN11 KIT JAK2
29 essential thrombocythemia 31.1 U2AF1 TET2 SRSF2 SETBP1 KIT JAK2
30 leukemia, acute lymphoblastic 31.1 U2AF1 TOP1 RUNX1 PTPN11 KIT JAK2
31 mastocytosis, cutaneous 31.0 U2AF1 TET2 SRSF2 KIT ASXL1
32 myeloma, multiple 31.0 U2AF1 TET2 PTPN11 NF1 JAK2 FLT3
33 myeloid sarcoma 31.0 U2AF1 KIT FLT3
34 leukemia, acute monocytic 31.0 U2AF1 FLT3 CSF1
35 chronic leukemia 30.9 U2AF1 TET2 SRSF2 SETBP1 PDGFRB KIT
36 platelet disorder, familial, with associated myeloid malignancy 30.9 RUNX1 ETV6
37 wilms tumor 1 30.9 U2AF1 TET2 NF1 KIT FLT3 CSF2
38 refractory cytopenia with multilineage dysplasia 30.9 U2AF1 TET2 SETBP1 GATA2 ASXL1
39 b-lymphoblastic leukemia/lymphoma 30.9 U2AF1 KIT FLT3 ETV6
40 langerhans cell histiocytosis 30.8 U2AF1 CSF2 CSF1
41 connective tissue disease 30.8 U2AF1 TOP1 NF1 KIT JAK2 CSF2
42 blood platelet disease 30.8 U2AF1 TET2 SRSF2 RUNX1 KIT JAK2
43 acute promyelocytic leukemia 30.7 U2AF1 TET2 RUNX1 KIT GATA2 FLT3
44 peripheral nervous system disease 30.7 U2AF1 TOP1 NF1 KIT JAK2 CSF2
45 rasopathy 30.7 U2AF1 SETBP1 PTPN11 PDGFRB NF1 KIT
46 vexas syndrome 30.7 U2AF1 TET2 ASXL1
47 systemic mastocytosis with associated hematologic neoplasm 30.6 TET2 SRSF2 KIT ASXL1
48 immunodeficiency 21 30.6 U2AF1 SETBP1 GATA2 FLT3 ASXL1
49 myeloproliferative disorder, chronic, with eosinophilia 30.6 PDGFRB ETV6
50 paroxysmal nocturnal hemoglobinuria 30.6 U2AF1 FLT3 CSF3R CSF2

Graphical network of the top 20 diseases related to Chronic Myelomonocytic Leukemia:



Diseases related to Chronic Myelomonocytic Leukemia

Symptoms & Phenotypes for Chronic Myelomonocytic Leukemia

UMLS symptoms related to Chronic Myelomonocytic Leukemia:


fatigue; fever; night sweats

GenomeRNAi Phenotypes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

25 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.84 CSF3R
2 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.84 CSF1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.84 U2AF1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.84 CSF3R
5 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.84 CSF3R TOP1 U2AF1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.84 CSF3R
7 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.84 CSF3R
8 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.84 CSF3R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.84 CSF1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.84 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.84 U2AF1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.84 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.84 CSF3R
14 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.84 CSF3R
15 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.84 CSF1 KIT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.84 CSF1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.84 CSF2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.84 CSF2 CSF3R U2AF1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-38 9.84 TOP1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.84 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.84 CSF2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 KIT U2AF1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-89 9.84 U2AF1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.84 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.84 U2AF1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.84 KIT

MGI Mouse Phenotypes related to Chronic Myelomonocytic Leukemia:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 ASXL1 CSF1 CSF2 ETV6 FLT3 GATA2
2 endocrine/exocrine gland MP:0005379 10.43 ASXL1 CSF1 CSF2 CSF3R ETV6 FLT3
3 growth/size/body region MP:0005378 10.41 ASXL1 CSF1 CSF2 CSF3R ETV6 FLT3
4 neoplasm MP:0002006 10.38 ASXL1 CSF2 ETV6 FLT3 HIP1 JAK2
5 cellular MP:0005384 10.38 ASXL1 CSF1 CSF2 CSF3R ETV6 FLT3
6 nervous system MP:0003631 10.32 CSF1 CSF2 CSF3R GATA2 HIP1 JAK2
7 immune system MP:0005387 10.31 ASXL1 CSF1 CSF2 CSF3R ETV6 FLT3
8 cardiovascular system MP:0005385 10.3 CSF1 CSF2 CSF3R ETV6 GATA2 JAK2
9 normal MP:0002873 10.29 ETV6 GATA2 HIP1 JAK2 KIT NF1
10 liver/biliary system MP:0005370 10.27 ASXL1 CSF1 ETV6 HIP1 JAK2 KIT
11 behavior/neurological MP:0005386 10.21 ASXL1 CSF1 CSF2 HIP1 JAK2 KIT
12 embryo MP:0005380 10.16 CSF2 ETV6 GATA2 JAK2 KIT NF1
13 no phenotypic analysis MP:0003012 10.13 CSF1 ETV6 FLT3 KIT PTPN11 RUNX1
14 hematopoietic system MP:0005397 10.09 ASXL1 CSF1 CSF2 CSF3R ETV6 FLT3
15 craniofacial MP:0005382 10.04 ASXL1 CSF1 CSF2 KIT NF1 PDGFRB
16 skeleton MP:0005390 10.03 ASXL1 CSF1 CSF2 ETV6 FLT3 HIP1
17 hearing/vestibular/ear MP:0005377 10.02 CSF1 GATA2 KIT NF1 PTPN11 U2AF1
18 reproductive system MP:0005389 10.02 CSF1 CSF2 CSF3R GATA2 HIP1 JAK2
19 respiratory system MP:0005388 9.97 CSF1 CSF2 HIP1 JAK2 KIT NF1
20 mortality/aging MP:0010768 9.93 ASXL1 CSF1 CSF2 CSF3R ETV6 FLT3
21 integument MP:0010771 9.32 CSF1 CSF2 ETV6 JAK2 KIT NF1

Drugs & Therapeutics for Chronic Myelomonocytic Leukemia

Drugs for Chronic Myelomonocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 312)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
homoharringtonine Phase 4 3628
2
Daunorubicin Approved Phase 3 20830-81-3 30323
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
4
Lenograstim Approved, Investigational Phase 3 135968-09-1
5
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
6
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
7
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
8
Aldesleukin Approved Phase 3 110942-02-4
9
Allopurinol Approved Phase 3 315-30-0 2094 135401907
10
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
11
Hydroxyurea Approved Phase 3 127-07-1 3657
12
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
13
Busulfan Approved, Investigational Phase 3 55-98-1 2478
14
Etoposide Approved Phase 3 33419-42-0 36462
15
Asparaginase Escherichia coli Approved, Investigational Phase 3 9015-68-3
16
Tioguanine Approved Phase 3 154-42-7 2723601
17
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
18
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
19
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
20
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
21
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 2826718
22
Lenalidomide Approved Phase 3 191732-72-6 216326
23
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
24
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
25
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
26
Lonafarnib Approved, Investigational Phase 3 193275-84-2 148195
27
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643
28
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
29
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
30
Pevonedistat Investigational Phase 3 905579-51-3 49831043
31 Anti-Infective Agents Phase 3
32 Antineoplastic Agents, Hormonal Phase 3
33 Hormones Phase 3
34 Antifungal Agents Phase 3
35 Hormone Antagonists Phase 3
36 Antiemetics Phase 3
37 glucocorticoids Phase 3
38 Anti-Inflammatory Agents Phase 3
39 BB 1101 Phase 3
40 Gastrointestinal Agents Phase 3
41 Cytochrome P-450 Enzyme Inhibitors Phase 3
42 Anti-Retroviral Agents Phase 3
43 Interleukin-2 Phase 3
44 Anti-HIV Agents Phase 3
45 Analgesics, Non-Narcotic Phase 3
46 Emetics Phase 3
47
Etoposide phosphate Phase 3 16760419
48 ON 01910 Phase 3
49 N-Methylaspartate Phase 3
50 Hydrocortisone-17-butyrate Phase 3

Interventional clinical trials:

(show top 50) (show all 298)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of Azacytidine Combined With HAG Regimen Versus Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy: a Prospective, Randomized Controlled Trial Recruiting NCT03873311 Phase 4 Azacytidine, HAG Regimen;Azacytidine
2 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
3 A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents Completed NCT02907359 Phase 3 Guadecitabine
4 A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML) Completed NCT02214407 Phase 3 Decitabine;HYDROXYUREA
5 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
6 Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine Completed NCT01928537 Phase 3 rigosertib sodium
7 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
8 Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine Completed NCT01241500 Phase 3 ON 01910.Na
9 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
10 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
11 A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
12 A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) Recruiting NCT04256317 Phase 2, Phase 3 Azacitidine;ASTX030 (cedazuridine + azacitidine);Cedazuridine
13 Graft vs Host Disease Prophylaxis in Unrelated Donor Transplantation: a Randomized Clinical Trial Comparing PTCY vs ATG (GRAPPA) Recruiting NCT05153226 Phase 3 Cyclophosphamide
14 A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) Active, not recruiting NCT04266301 Phase 3 MBG453;Azacitidine;Placebo
15 A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) Active, not recruiting NCT03306264 Phase 3 ASTX727;Dacogen
16 A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia Active, not recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
17 A MULTI-CENTER CONTINUATION STUDY EVALUATING AZACITIDINE WITH OR WITHOUT GLASDEGIB (PF-04449913) IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA Active, not recruiting NCT04842604 Phase 3 Glasdegib;Azacitidine
18 Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid�) Alone and in Combination With Epoetin Alfa (Procrit�) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia Active, not recruiting NCT00843882 Phase 3 Lenalidomide
19 A Pivotal Randomized Study of Lonafarnib Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia Terminated NCT00109538 Phase 3 Lonafarnib
20 Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate
21 A Phase I/II, Open-Label, Multicenter Study of the Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML) Unknown status NCT03040401 Phase 1, Phase 2 Cohort 1, Ceplene® and Proleukin®;Cohort 2, Ceplene® and Proleukin®;Cohort 3, Ceplene® and Proleukin®
22 A Phase I/II Study of Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Unknown status NCT01368757 Phase 1, Phase 2 Revlimid
23 A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk MDS and AML With Del 5q Unknown status NCT00885508 Phase 2 Lenalidomide
24 A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of Mutation TP53 (TP53) Mutant Myeloid Neoplasms Unknown status NCT03588078 Phase 1, Phase 2 APR-246;Azacitidine
25 Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure Unknown status NCT01133886 Phase 2 Decitabine
26 Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability Unknown status NCT01404741 Phase 2
27 A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity Completed NCT01776723 Phase 1, Phase 2 Ruxolitinib
28 An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Completed NCT01736683 Phase 2 Sotatercept
29 A Phase II Study of Sunitinib Malate (Sutent®; SU11248) in Patients With Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Completed NCT00451048 Phase 2 sunitinib malate
30 A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myelogenous Leukemia Completed NCT02610777 Phase 2 Azacitidine;Pevonedistat
31 Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC) Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
32 A Pilot Study of the Safety and Efficacy of Imatinib in Reducing Monocytosis or Leukocytosis in Patients With Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia, Respectively Completed NCT00079313 Phase 2 Imatinib
33 A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat (LBH589) Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). Completed NCT00946647 Phase 1, Phase 2 Panobinostat (LBH589);5-Azacytidine
34 A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other Myelodysplastic /Myeloproliferative Neoplasias, and Acute Myeloid Leukemia Completed NCT02807272 Phase 2 Tipifarnib
35 A Phase II Study of Gleevec (Imatinib Mesylate) In Patients With BCR-Negative Myeloproliferative Disorders Including Patients With Idiopathic Myelofibrosis With Myeloid Dysplasia or Chronic Myelomonocytic Leukemia Completed NCT00136409 Phase 2 Imatinib mesylate
36 A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasia Completed NCT00313586 Phase 2 Azacitidine;Entinostat
37 A Phase I/II Study of Eltrombopag in Patients With Chronic Myelomonocytic Leukemia and Thrombocytopenia Completed NCT02323178 Phase 1, Phase 2 eltrombopag
38 A Phase II Study of Decitabine in Patients With Chronic Myelomonocytic Leukemia Completed NCT01098084 Phase 2 Decitabine
39 A Phase II Multicenter Open-label Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia Completed NCT01251627 Phase 2 Decitabine
40 A Phase 2 Study of Azacitidine in Chronic Myelomonocytic Leukemia (CMML) Completed NCT01235117 Phase 2 azacitidine
41 A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia (CMML) Completed NCT01350947 Phase 2 5-Azacitidine
42 A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response Completed NCT02197676 Phase 2 SGI-110 administration
43 Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft Completed NCT02556931 Phase 2 Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
44 A Multi-Center Study of Conditioning With Treosulfan, Fludarabine and Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS), and Acute Lymphoblastic Leukemia (ALL) Completed NCT00860574 Phase 2 treosulfan;fludarabine phosphate;tacrolimus;methotrexate
45 A Phase II Study of and Oral Histone Deacytylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies Completed NCT00462605 Phase 2 entinostat;sargramostim
46 A Phase 2 Study of WEE1 Inhibition With AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome Completed NCT02666950 Phase 2 Cytarabine;WEE1 Inhibitor AZD1775
47 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
48 Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial Completed NCT00397813 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
49 Very Low-dose Total Body Irradiation in Combination With Total Lymphoid Irradiation and Anti-Thymocyte Globulin to Improve Donor Engraftment in Patients Undergoing Non-Myeloablative Hematopoietic Cell Transplantation Completed NCT03734601 Phase 2 Anti-thymocyte globulin (ATG);Tacrolimus;Mycophenolate mofetil (MMF)
50 A Feasibility Study of "Early" Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasms Completed NCT02756572 Phase 2 Cladribine;Cyclosporine;Cytarabine;Fludarabine Phosphate;Melphalan;Mitoxantrone Hydrochloride;Mycophenolate Mofetil;Sirolimus;Melphalan Hydrochloride

Search NIH Clinical Center for Chronic Myelomonocytic Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Myelomonocytic Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Chronic Myelomonocytic Leukemia:
Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Chronic Myelomonocytic Leukemia:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD) PMIDs: 9828244

Genetic Tests for Chronic Myelomonocytic Leukemia

Genetic tests related to Chronic Myelomonocytic Leukemia:

# Genetic test Affiliating Genes
1 Chronic Myelomonocytic Leukemia 28

Anatomical Context for Chronic Myelomonocytic Leukemia

Organs/tissues related to Chronic Myelomonocytic Leukemia:

MalaCards : Bone Marrow, Myeloid, Monocytes, Bone, Spleen, Liver, Nk Cells

Publications for Chronic Myelomonocytic Leukemia

Articles related to Chronic Myelomonocytic Leukemia:

(show top 50) (show all 2317)
# Title Authors PMID Year
1
ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. 5
24854988 2014
2
Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia. 5
23873282 2014
3
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. 5
21705501 2011
4
The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation. 5
19345670 2009
5
FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. 5
16761019 2006
6
RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. 53 62
19282830 2009
7
Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways. 53 62
19100521 2009
8
Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. 53 62
18555525 2008
9
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. 53 62
18925961 2008
10
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. 53 62
18055864 2008
11
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. 53 62
17936561 2007
12
The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. 53 62
17643100 2007
13
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. 53 62
16955510 2006
14
Atypical myeloproliferative disorders: diagnosis and management. 53 62
16610578 2006
15
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. 53 62
16037387 2005
16
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. 53 62
15725481 2005
17
Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. 53 62
15995322 2005
18
Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. 53 62
15068895 2004
19
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. 53 62
12908555 2003
20
Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo. 53 62
12384142 2002
21
Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. 53 62
11588050 2001
22
Regulation of the Src homology 2-containing inositol 5-phosphatase SHIP1 in HIP1/PDGFbeta R-transformed cells. 53 62
11287412 2001
23
Tyrosine phosphorylation of proteins in primary human myeloid leukemic cells stimulated by macrophage colony-stimulating factor: analysis by disease type and comparison with normal human hematopoietic cells. 53 62
11372744 2001
24
Protease inhibitor 10 inhibits tumor necrosis factor alpha -induced cell death. Evidence for the formation of intracellular high M(r) protease inhibitor 10-containing complexes. 53 62
10871600 2000
25
Thrombopoietin and myelodysplastic syndromes. 53 62
11039665 2000
26
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. 53 62
11105617 2000
27
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. 53 62
10784392 2000
28
Priming effects of macrophage colony-stimulating factor on monocytic leukemia cells in combination with chemotherapy: induction of programmed cell death in vivo. 53 62
10784404 2000
29
Transforming properties of the Huntingtin interacting protein 1/ platelet-derived growth factor beta receptor fusion protein. 53 62
10428802 1999
30
Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. 53 62
9834234 1998
31
Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). 53 62
9616134 1998
32
Myc is essential for transformation by TEL/platelet-derived growth factor receptor beta (PDGFRbeta). 53 62
9558390 1998
33
Analysis of the granulocyte colony-stimulating factor receptor gene structure using PCR-SSCP in myeloid leukemia and myelodysplastic syndrome. 53 62
9548419 1998
34
Expression of bomapin, a novel human serpin, in normal/malignant hematopoiesis and in the monocytic cell lines THP-1 and AML-193. 53 62
9454755 1998
35
Feasibility of peripheral blood stem cell (PBSC) and peripheral blood mononuclear cell (PBMNC) separation in children with a body weight below 20 KG. 53 62
9180913 1997
36
Prolonged extreme thrombocytosis associated with neurofibromatosis type 1. 53 62
9042140 1997
37
The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. 53 62
8962143 1996
38
The effects of thrombopoietin on the growth of acute myeloblastic leukemia cells. 53 62
9031083 1996
39
ETV6 gene rearrangements in hematopoietic malignant disorders. 53 62
9031109 1996
40
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. 53 62
8839838 1996
41
Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells. 53 62
8879210 1996
42
Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells. 53 62
8751457 1996
43
Lymphoblastic transformation of chronic myelomonocytic leukemia in an infant. 53 62
8756090 1996
44
In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels. 53 62
9816264 1996
45
bcr gene rearrangement analysis in myeloproliferative disorders other than chronic myelogenous leukemia. 53 62
8818385 1996
46
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. 53 62
7479840 1995
47
The levels of granulocyte colony-stimulating factor in the plasma of the bone marrow aspirate in various hematological disorders. 53 62
7549901 1995
48
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. 53 62
7761424 1995
49
Exon trap analysis of a NF1 splice-site mutation in a chronic myelomonocytic leukemia patient. 53 62
7769857 1995
50
Prognostic value of c-mpl expression in myelodysplastic syndromes. 53 62
7539513 1995

Variations for Chronic Myelomonocytic Leukemia

ClinVar genetic disease variations for Chronic Myelomonocytic Leukemia:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ETV6, FLT3 t(12;13)(p13.2;q12.2) TRANS Likely Pathogenic
590266 GRCh37: 12:12037520-12037521
GRCh38:

Copy number variations for Chronic Myelomonocytic Leukemia from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 160282 22 11800000 24300000 Translocation Chronic myelomonocytic leukemia
2 228217 7 75001344 75206215 Translate HIP1 Chronic myelomonocytic leukemia
3 247204 9 129300000 140273252 Translocation Chronic myelomonocytic leukemia

Expression for Chronic Myelomonocytic Leukemia

Search GEO for disease gene expression data for Chronic Myelomonocytic Leukemia.

Pathways for Chronic Myelomonocytic Leukemia

Pathways related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 ETV6 FLT3 HIP1 JAK2 KIT NF1
2
Show member pathways
13.26 PDGFRB KIT JAK2 FLT3 CSF3R CSF2
3
Show member pathways
13.12 PTPN11 PDGFRB KIT JAK2 CSF3R CSF2
4
Show member pathways
12.73 PTPN11 PDGFRB NF1 KIT JAK2 HIP1
5
Show member pathways
12.72 PDGFRB KIT JAK2 FLT3 CSF3R CSF1
6 12.68 PTPN11 PDGFRB KIT JAK2 FLT3
7
Show member pathways
12.51 PTPN11 PDGFRB KIT JAK2 CSF3R
8 12.45 RUNX1 KIT JAK2 GATA2
9 12.41 PDGFRB KIT FLT3 CSF2 CSF1 ASXL1
10
Show member pathways
12.12 CSF1 CSF2 JAK2 PTPN11
11
Show member pathways
11.89 PTPN11 KIT JAK2
12 11.88 PDGFRB KIT JAK2 FLT3
13 11.85 PTPN11 KIT JAK2
14 11.82 PTPN11 PDGFRB NF1 KIT FLT3
15
Show member pathways
11.79 PTPN11 KIT JAK2
16
Show member pathways
11.73 PDGFRB KIT FLT3
17
Show member pathways
11.62 PDGFRB KIT FLT3
18
Show member pathways
11.56 PTPN11 JAK2 CSF2
19 11.43 KIT FLT3 CSF2 CSF1
20
Show member pathways
11.41 PTPN11 JAK2 CSF3R
21 11.39 PTPN11 PDGFRB JAK2
22 11.3 PDGFRB JAK2 CSF1
23 11.09 KIT FLT3 CSF3R CSF2 CSF1
24
Show member pathways
11.08 FLT3 KIT PDGFRB
25 10.88 PDGFRB KIT FLT3 CSF2 CSF1
26 10.86 RUNX1 PTPN11
27 10.8 PDGFRB JAK2
28 10.72 CSF2 CSF1
29
Show member pathways
10.62 RUNX1 CSF2

GO Terms for Chronic Myelomonocytic Leukemia

Cellular components related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 granulocyte macrophage colony-stimulating factor receptor complex GO:0030526 8.92 JAK2 CSF2

Biological processes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.29 PDGFRB KIT JAK2 FLT3 CSF2 CSF1
2 positive regulation of cell migration GO:0030335 10.24 PDGFRB KIT JAK2 CSF2 CSF1
3 peptidyl-tyrosine phosphorylation GO:0018108 10.19 FLT3 JAK2 KIT PDGFRB
4 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 10.16 PDGFRB KIT FLT3 CSF1
5 positive regulation of MAPK cascade GO:0043410 10.15 PDGFRB KIT JAK2 FLT3
6 regulation of cell population proliferation GO:0042127 10.02 NF1 KIT FLT3 CSF2
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.97 FLT3 JAK2 KIT PDGFRB
8 cytokine-mediated signaling pathway GO:0019221 9.96 PTPN11 KIT JAK2 FLT3 CSF3R
9 platelet-derived growth factor receptor signaling pathway GO:0048008 9.95 PTPN11 PDGFRB JAK2
10 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.93 PDGFRB KIT FLT3
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.92 KIT JAK2 FLT3 CSF2
12 homeostasis of number of cells within a tissue GO:0048873 9.91 PTPN11 GATA2 CSF1
13 response to fluid shear stress GO:0034405 9.9 PDGFRB CSF2
14 myeloid progenitor cell differentiation GO:0002318 9.88 KIT FLT3
15 response to organic cyclic compound GO:0014070 9.88 TET2 PDGFRB JAK2 CSF1
16 positive regulation of leukocyte proliferation GO:0070665 9.87 JAK2 CSF2
17 granulocyte-macrophage colony-stimulating factor signaling pathway GO:0038157 9.83 CSF2 JAK2
18 mast cell proliferation GO:0070662 9.81 KIT NF1
19 myeloid leukocyte migration GO:0097529 9.8 CSF1 NF1
20 regulation of MAPK cascade GO:0043408 9.72 PTPN11 NF1 KIT
21 positive regulation of response to stimulus GO:0048584 9.61 KIT FLT3
22 hemopoiesis GO:0030097 9.61 RUNX1 KIT GATA2 FLT3 ASXL1
23 positive regulation of protein modification process GO:0031401 9.33 PDGFRB KIT FLT3
24 myeloid cell differentiation GO:0030099 9.1 TET2 JAK2 GATA2 CSF2

Molecular functions related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide hormone receptor binding GO:0051428 9.46 PTPN11 JAK2
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 PDGFRB KIT FLT3
3 protein tyrosine kinase activity GO:0004713 9.23 PDGFRB KIT JAK2 FLT3

Sources for Chronic Myelomonocytic Leukemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....